About Us
“For EMBARK, we have gathered together the wisdom of 28 of the world’s leading experts in psychedelic practice as teachers, supervisors, and advisors for our program. They are the recognized leaders in their fields, and I’m deeply grateful for their skill, integrity, and heartfelt teachings,” said Dr. Alex Belser, Chief Clinical Officer at Cybin.
Anthony Back, MD
Clinical Advisory Board, Faculty
Professor of Medicine at the University of Washington in Seattle, and the Fred Hutchinson Cancer Research Center. He is the Principal Investigator for a Phase 2 clinical trial to treat frontline clinicians experiencing COVID-related burnout and distress.
Alex Belser, PhD
EMBARK Co-Creator, Faculty
Co-creator of EMBARK, Chief Clinical Officer at Cybin, Chair of Cybin’s Clinical Advisory Board, and Co-Investigator on a psilocybin clinical trial at Yale University.
Maurizio Fava, MD
Clinical Advisory Board
Psychiatrist-in-Chief in the Department of Psychiatry at Massachusetts General Hospital, and an Associate Dean for Clinical and Translational Research at Harvard Medical School.
Lynn Marie Morski, MD, JD
Clinical Advisory Board
President of the Psychedelic Medicine Association.
Alex Kelman, PhD
Head of Therapies, Faculty
Head of Therapies at Cybin and Attending Psychologist and Assistant Clinical Professor at the University of California, Los Angeles.
Tom Laughren, MD
Clinical Advisory Board
Director at Laughren Psychopharm Consulting, LLC, and the Former Director of FDA’s Division of Psychiatry Products.
Bill Brennan, PhD
EMBARK Co-Creator, Faculty, Clinical Supervisor
EMBARK co-creator, clinical supervisor, core faculty and author researching best practices for psychedelic psychotherapy.
NiCole T. Buchanan, PhD
Faculty
Clinical-Community Psychologist, Professor, and Justice, Equity, Diversity, and Inclusion (JEDI) consultant.
Stacia Butterfield
Faculty
Certified Holotropic Breathwork practitioner and a teacher with Grof Transpersonal Training.
Jeffrey Guss, MD
Faculty, Clinical Supervisor
Psychiatrist, psychoanalyst, researcher and teacher specializing in psychoanalytic therapy and psychedelic therapy. He is a Lead Trainer at Fluence and Clinical Assistant Professor of Psychiatry at the NYU School of Medicine.
Amir Inamdar, MBBS, DNB (Psych), MFPM
Chief Medical Officer
Psychiatrist, pharmaceutical physician, drug developer and Cybin’s Chief Medical Officer.
Manuela Mischke-Reeds, MA, MFT
Faculty
Somatic psychotherapist and teacher, co-director of the Hakomi Institute of California, Chief Mental Health Officer at Abroad.
Marcela Ot’alora G, MA, LPC
Faculty
Trainer, researcher and advocate for the safe and ethical use of psychedelic therapy. She is a lead trainer for the MAPS MDMA Therapy Training Program.
Florie St. Aime, LCSW
Faculty
Invites others into liberation practices through social justice organizing, group facilitation, individual psychotherapy, supervision and holding sacred space.
Kylea Taylor, MFT
Faculty
Created and teaches InnerEthics®, a self-reflective approach to ethics education that she first described in her book The Ethics of Caring.
Ingmar Gorman, PhD
Advisor
CEO and Co-Founder of Fluence, a clinical psychologist, and former site Co-Principal Investigator and therapist for MAPS MDMA-assisted psychotherapy trials.
Charlotte Harrison
Advisor
Clinical trial consultant collaborating with the Cybin team on protocol and training development. She has worked in clinical research for over a decade, including overseeing MAPS’ MDMA-assisted psychotherapy program.
Franklin King, MD,
Clinical Supervisor
Instructor at Harvard Medical School and psychiatrist at Massachusetts General Hospital where he serves as the Director of Training and Education at the Center for Neuroscience of Psychedelics.
Robert Krause DNP APRN-BC
Clincal Supervisor
Co-director of Centered PLLC, researcher, therapist, and educator. He has lectured at Yale University and is visiting faculty in the Consciousness Studies Department at the Graduate Institute. A graduate of CIIS’s founding cohort in Psychedelic Assisted Therapy, he is also a MAPS therapist in an expanded access protocol.
John Krystal, MD
Subject Matter Expert; Advisor
Chair at Yale University’s Department of Psychiatry and Co-Director of Yale’s Center for Clinical Investigation.
Dennis McKenna, PhD
Subject Matter Expert; Advisor
Author or co-author of three books and over 50 peer-reviewed papers on the chemistry, ethnopharmacology, and neuroscience of psychedelics, as well as other botanical medicines. He is a founding board member of Heffter Research Institute, and the founder and President of the McKenna Academy of Natural Philosophy, which is focused on psychedelic education and the preservation of traditional knowledge, facilitating its integration with scientific knowledge.
Elizabeth Nielson, PhD
Advisor
CVO and Co-Founder of Fluence, a site Co-Principal Investigator and therapist for MAPS MDMA-assisted psychotherapy trials, and an investigator in NYU’s study of psilocybin-assisted psychotherapy for Alcohol Use Disorder.
Jordan Sloshower, MD, MSc
Clinical Supervisor
Psychiatrist and researcher at Yale University where he serves as an investigator and therapist in several clinical trials of psilocybin-assisted therapy. Jordan is also a clinical investigator in MAPS’ Expanded Access Program for MDMA-assisted therapy of PTSD and serves as a lead trainer with Usona Institute’s psilocybin facilitator training program.
Andrew Solomon, PhD
Guest Faculty
Professor of clinical psychology at Columbia and a lecturer in psychiatry at Yale, is the National Book Award-winning author of The Noonday Demon and Far from the Tree, a writer for The New Yorker, and a writer and speaker on politics, psychology, and the arts.